Perioperative Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy
Author Information
Author(s): Yan Tristan D, Stuart Oswald A, Yoo Dal, Sugarbaker Paul H
Primary Institution: Washington Cancer Institute, Washington DC, USA
Hypothesis
Can cytoreductive surgery combined with perioperative intraperitoneal chemotherapy improve survival in patients with peritoneal surface malignancy?
Conclusion
The combination of cytoreductive surgery and perioperative intraperitoneal chemotherapy has shown improved survival rates in selected patients with peritoneal surface malignancy.
Supporting Evidence
- The median survival for patients treated with cytoreductive surgery and IPHC was 50 months.
- The 5-year survival rate for these patients was 44%.
- Another study showed that overall survival rates for patients with appendiceal neoplasms treated with similar methods were 63%, 54%, and 50% at 5, 10, and 20 years respectively.
Takeaway
Doctors are using a special type of chemotherapy during and after surgery to help people with certain stomach cancers live longer.
Methodology
This review discusses various treatment regimens of perioperative intraperitoneal chemotherapy used in conjunction with cytoreductive surgery.
Limitations
There is no consensus on the most effective chemotherapy regimens, and treatment protocols vary by institution.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website